메뉴 건너뛰기




Volumn 41, Issue 3, 2018, Pages 101-108

The Risk of Diarrhea and Colitis in Patients with Advanced Melanoma Undergoing Immune Checkpoint Inhibitor Therapy: A Systematic Review and Meta-Analysis

Author keywords

colitis; diarrhea; immunotherapy; melanoma

Indexed keywords

ATEZOLIZUMAB; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 INHIBITOR; DURVALUMAB; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 INHIBITOR; TICILIMUMAB; UNCLASSIFIED DRUG; CTLA4 PROTEIN, HUMAN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; PROGRAMMED DEATH 1 RECEPTOR; TUMOR MARKER;

EID: 85044349953     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0000000000000213     Document Type: Review
Times cited : (59)

References (52)
  • 1
    • 79952613370 scopus 로고    scopus 로고
    • Systematic review of medical treatment in melanoma: Current status and future prospects
    • Garbe C, Eigentler TK, Keilholz U, et al. Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist. 2011;16:5-24.
    • (2011) Oncologist , vol.16 , pp. 5-24
    • Garbe, C.1    Eigentler, T.K.2    Keilholz, U.3
  • 2
    • 0029086370 scopus 로고
    • Prognostic factors in 1, 521 melanoma patients with distant metastases
    • Barth A, Wanek LA, Morton DL. Prognostic factors in 1, 521 melanoma patients with distant metastases. J Am Coll Surg. 1995;181:193-201.
    • (1995) J Am Coll Surg , vol.181 , pp. 193-201
    • Barth, A.1    Wanek, L.A.2    Morton, D.L.3
  • 3
    • 84874605864 scopus 로고    scopus 로고
    • Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma
    • Ribas A, Kefford R, Marshall MA, et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Onc. 2013;31:616-622.
    • (2013) J Clin Onc , vol.31 , pp. 616-622
    • Ribas, A.1    Kefford, R.2    Marshall, M.A.3
  • 4
    • 69949095926 scopus 로고    scopus 로고
    • A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma
    • Weber J, Thompson JA, Hamid O, et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res. 2009;15:5591-5598.
    • (2009) Clin Cancer Res , vol.15 , pp. 5591-5598
    • Weber, J.1    Thompson, J.A.2    Hamid, O.3
  • 5
    • 61449090474 scopus 로고    scopus 로고
    • Phase I/II trial of tremelimumab in patients with metastatic melanoma
    • Camacho LH, Antonia S, Sosman J, et al. Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Onc. 2009;27:1075-1081.
    • (2009) J Clin Onc , vol.27 , pp. 1075-1081
    • Camacho, L.H.1    Antonia, S.2    Sosman, J.3
  • 6
    • 75249100054 scopus 로고    scopus 로고
    • Ipilimumab monotherapy in patients with pretreated advanced melanoma: A randomised, double-blind, multicentre, phase 2, dose-ranging study
    • Wolchok JD, Neyns B, Linette G, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2010;11:155-164.
    • (2010) Lancet Oncol , vol.11 , pp. 155-164
    • Wolchok, J.D.1    Neyns, B.2    Linette, G.3
  • 7
    • 33846465547 scopus 로고    scopus 로고
    • Immunostimulatory monoclonal antibodies for cancer therapy
    • Melero I, Hervas-Stubbs S, Glennie M, et al. Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer. 2007;7:95-106.
    • (2007) Nat Rev Cancer , vol.7 , pp. 95-106
    • Melero, I.1    Hervas-Stubbs, S.2    Glennie, M.3
  • 8
  • 9
    • 42649125225 scopus 로고    scopus 로고
    • PD-1 and its ligands in tolerance and immunity
    • Keir ME, Butte MJ, Freeman GJ, et al. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677-704.
    • (2008) Annu Rev Immunol , vol.26 , pp. 677-704
    • Keir, M.E.1    Butte, M.J.2    Freeman, G.J.3
  • 10
    • 84858766182 scopus 로고    scopus 로고
    • The blockade of immune checkpoints in cancer immunotherapy
    • Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252-264.
    • (2012) Nat Rev Cancer , vol.12 , pp. 252-264
    • Pardoll, D.M.1
  • 11
    • 68149155982 scopus 로고    scopus 로고
    • Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies
    • Peggs KS, Quezada SA, Chambers CA, et al. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med. 2009;206:1717-1725.
    • (2009) J Exp Med , vol.206 , pp. 1717-1725
    • Peggs, K.S.1    Quezada, S.A.2    Chambers, C.A.3
  • 12
    • 84898973055 scopus 로고    scopus 로고
    • Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab
    • Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32:1020-1030.
    • (2014) J Clin Oncol , vol.32 , pp. 1020-1030
    • Topalian, S.L.1    Sznol, M.2    McDermott, D.F.3
  • 13
    • 84931083080 scopus 로고    scopus 로고
    • Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, phase 3 trial
    • Weber JS, D?Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16:375-384.
    • (2015) Lancet Oncol , vol.16 , pp. 375-384
    • Weber, J.S.1    Dangelo, S.P.2    Minor, D.3
  • 14
    • 84971619894 scopus 로고    scopus 로고
    • Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: Early analysis of a non-randomised, open-label, phase 2 trial
    • Goldberg SB, Gettinger SN, Mahajan A, et al. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol. 2016;17:976-983.
    • (2016) Lancet Oncol , vol.17 , pp. 976-983
    • Goldberg, S.B.1    Gettinger, S.N.2    Mahajan, A.3
  • 15
    • 85033400433 scopus 로고    scopus 로고
    • Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma
    • Weber J, Mandala M, Del Vecchio M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377:1824-1835.
    • (2017) N Engl J Med , vol.377 , pp. 1824-1835
    • Weber, J.1    Mandala, M.2    Del Vecchio, M.3
  • 16
    • 84929481481 scopus 로고    scopus 로고
    • Pembrolizumab versus ipilimumab in advanced melanoma
    • Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372: 2521-2532.
    • (2015) N Engl J Med , vol.372 , pp. 2521-2532
    • Robert, C.1    Schachter, J.2    Long, G.V.3
  • 17
    • 78449244037 scopus 로고    scopus 로고
    • The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications
    • Di Giacomo AM, Biagioli M, Maio M. The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications. Semin Oncol. 2010;37:499-507.
    • (2010) Semin Oncol , vol.37 , pp. 499-507
    • Di Giacomo, A.M.1    Biagioli, M.2    Maio, M.3
  • 18
    • 79959772576 scopus 로고    scopus 로고
    • Ipilimumab plus dacarbazine for previously untreated metastatic melanoma
    • Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364:2517-2526.
    • (2011) N Engl J Med , vol.364 , pp. 2517-2526
    • Robert, C.1    Thomas, L.2    Bondarenko, I.3
  • 19
    • 77954801079 scopus 로고    scopus 로고
    • Improved survival with ipilimumab in patients with metastatic melanoma
    • Hodi FS, O?Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711-723.
    • (2010) N Engl J Med , vol.363 , pp. 711-723
    • Hodi, F.S.1    Oday, S.J.2    McDermott, D.F.3
  • 20
    • 69149107165 scopus 로고    scopus 로고
    • Preferred reporting items for systematic reviews and meta-Analyses: The PRISMA statement
    • Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-Analyses: the PRISMA statement. Ann Intern Med. 2009;151:264-269.
    • (2009) Ann Intern Med , vol.151 , pp. 264-269
    • Moher, D.1    Liberati, A.2    Tetzlaff, J.3
  • 22
    • 36849093844 scopus 로고    scopus 로고
    • Patient-reported outcomes and the evolution of adverse event reporting in oncology
    • Trotti A, Colevas AD, Setser A, et al. Patient-reported outcomes and the evolution of adverse event reporting in oncology. J Clin Oncol. 2007;25:5121-5127.
    • (2007) J Clin Oncol , vol.25 , pp. 5121-5127
    • Trotti, A.1    Colevas, A.D.2    Setser, A.3
  • 23
    • 84863847959 scopus 로고    scopus 로고
    • Closing the gap between methodologists and end-users: R as computational back-end
    • Wallace BC, Dahabreh IJ, Trikalinos TA, et al. Closing the gap between methodologists and end-users: R as computational back-end. J Stat Softw. 2012;49:5.
    • (2012) J Stat Softw , vol.49 , pp. 5
    • Wallace, B.C.1    Dahabreh, I.J.2    Trikalinos, T.A.3
  • 24
    • 84863796659 scopus 로고    scopus 로고
    • Review Manager (RevMan) [Computer Program] Version 53. Copenhagen: The Nordic Cochrane Centre
    • Review Manager (RevMan) [Computer Program], Version 53. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration; 2014. Available at: http://community.cochrane. org/tools/review-production-tools/revman-5/about-revman-5.
    • (2014) The Cochrane Collaboration
  • 26
    • 84994874924 scopus 로고    scopus 로고
    • Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy
    • Eggermont AMM, Chiarion-Sileni V, Grob J-J, et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med. 2016;375:1845-1855.
    • (2016) N Engl J Med , vol.375 , pp. 1845-1855
    • Amm, E.1    Chiarion-Sileni, V.2    Grob, J.-J.3
  • 27
    • 84860446616 scopus 로고    scopus 로고
    • Ipilimumab in patients with melanoma and brain metastases: An open-label, phase 2 trial
    • Margolin K, Ernstoff MS, Hamid O, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 2012;13:459-465.
    • (2012) Lancet Oncol , vol.13 , pp. 459-465
    • Margolin, K.1    Ernstoff, M.S.2    Hamid, O.3
  • 28
    • 84929481482 scopus 로고    scopus 로고
    • Nivolumab and ipilimumab versus ipilimumab in untreated melanoma
    • Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372:2006-2017.
    • (2015) N Engl J Med , vol.372 , pp. 2006-2017
    • Postow, M.A.1    Chesney, J.2    Pavlick, A.C.3
  • 29
    • 84925222119 scopus 로고    scopus 로고
    • Nivolumab in previously untreated melanoma without BRAF mutation
    • Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320-330.
    • (2015) N Engl J Med , vol.372 , pp. 320-330
    • Robert, C.1    Long, G.V.2    Brady, B.3
  • 30
    • 84991110530 scopus 로고    scopus 로고
    • Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): An openlabel, randomised, phase 2 trial
    • Weber JS, Gibney G, Sullivan RJ, et al. Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an openlabel, randomised, phase 2 trial. Lancet Oncol. 2016;17:943-955.
    • (2016) Lancet Oncol , vol.17 , pp. 943-955
    • Weber, J.S.1    Gibney, G.2    Sullivan, R.J.3
  • 31
    • 85044389420 scopus 로고    scopus 로고
    • Open-label, multicenter, single-Arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma
    • Zimmer L, Eigentler TK, Kiecker F, et al. Open-label, multicenter, single-Arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma. J Transl Med. 2015;5:1-11.
    • (2015) J Transl Med , vol.5 , pp. 1-11
    • Zimmer, L.1    Eigentler, T.K.2    Kiecker, F.3
  • 32
    • 84938205998 scopus 로고    scopus 로고
    • Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): A randomised, controlled, phase 2 trial
    • Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015;16:908-918.
    • (2015) Lancet Oncol , vol.16 , pp. 908-918
    • Ribas, A.1    Puzanov, I.2    Dummer, R.3
  • 33
    • 84936147067 scopus 로고    scopus 로고
    • Combined nivolumab and ipilimumab or monotherapy in untreated melanoma
    • Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:23-34.
    • (2015) N Engl J Med , vol.373 , pp. 23-34
    • Larkin, J.1    Chiarion-Sileni, V.2    Gonzalez, R.3
  • 34
    • 76049092889 scopus 로고    scopus 로고
    • Phase II trial of tremelimumab (CP-675 206) in patients with advanced refractory or relapsed melanoma
    • Kirkwood JM, Lorigan P, Hersey P, et al. Phase II trial of tremelimumab (CP-675, 206) in patients with advanced refractory or relapsed melanoma. Clin Cancer Res. 2010;16:1042-1048.
    • (2010) Clin Cancer Res , vol.16 , pp. 1042-1048
    • Kirkwood, J.M.1    Lorigan, P.2    Hersey, P.3
  • 35
    • 84879045360 scopus 로고    scopus 로고
    • Randomized phase i pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma
    • Weber J, Hamid O, Amin A, et al. Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma. Cancer Immun. 2013;13:7.
    • (2013) Cancer Immun , vol.13 , pp. 7
    • Weber, J.1    Hamid, O.2    Amin, A.3
  • 36
    • 85014741205 scopus 로고    scopus 로고
    • Phase 1b study of pembrolizumab (MK-3475; Anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041
    • Yamazaki N, Takenouchi T, Fujimoto M, et al. Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041). Cancer Chemother Pharmacol. 2017;79:651-660.
    • (2017) Cancer Chemother Pharmacol , vol.79 , pp. 651-660
    • Yamazaki, N.1    Takenouchi, T.2    Fujimoto, M.3
  • 37
    • 85016813132 scopus 로고    scopus 로고
    • Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: A randomised, double-blind, multicentre, phase 3 trial
    • Ascierto PA, Del Vecchio M, Robert C, et al. Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2017;18:611-622.
    • (2017) Lancet Oncol , vol.18 , pp. 611-622
    • Ascierto, P.A.1    Del Vecchio, M.2    Robert, C.3
  • 38
    • 85005950533 scopus 로고    scopus 로고
    • Immunotherapy in melanoma: Recent advances and future directions
    • Franklin C, Livingstone E, Roesch A, et al. Immunotherapy in melanoma: recent advances and future directions. Eur J Surg Oncol. 2017;43:604-611.
    • (2017) Eur J Surg Oncol , vol.43 , pp. 604-611
    • Franklin, C.1    Livingstone, E.2    Roesch, A.3
  • 39
    • 33744792341 scopus 로고    scopus 로고
    • Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyteassociated antigen 4
    • Beck KE, Blansfield JA, Tran KQ, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyteassociated antigen 4. J Clin Oncol. 2006;24:2283-2289.
    • (2006) J Clin Oncol , vol.24 , pp. 2283-2289
    • Beck, K.E.1    Blansfield, J.A.2    Tran, K.Q.3
  • 40
    • 84864052441 scopus 로고    scopus 로고
    • Management of immunerelated adverse events and kinetics of response with ipilimumab
    • Weber JS, Kahler KC, Hauschild A. Management of immunerelated adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30:2691-2697.
    • (2012) J Clin Oncol , vol.30 , pp. 2691-2697
    • Weber, J.S.1    Kahler, K.C.2    Hauschild, A.3
  • 41
  • 42
    • 84964355523 scopus 로고    scopus 로고
    • Melanoma, version 2.2016, NCCN clinical practice guidelines in oncology
    • Colt DG, Thompson JA, Algazi A, et al. Melanoma, version 2.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2016;14:450-473.
    • (2016) J Natl Compr Canc Netw , vol.14 , pp. 450-473
    • Colt, D.G.1    Thompson, J.A.2    Algazi, A.3
  • 43
    • 0028867420 scopus 로고
    • Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4
    • Tivol EA, Borriello F, Schweitzer AN, et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 1995;3:541-547.
    • (1995) Immunity , vol.3 , pp. 541-547
    • Tivol, E.A.1    Borriello, F.2    Schweitzer, A.N.3
  • 44
    • 84879477789 scopus 로고    scopus 로고
    • Ipilimumab and its toxicities: A multidisciplinary approach
    • Fecher LA, Agarwala SS, Hodi FS, et al. Ipilimumab and its toxicities: a multidisciplinary approach. Oncologist. 2013;18: 733-743.
    • (2013) Oncologist , vol.18 , pp. 733-743
    • Fecher, L.A.1    Agarwala, S.S.2    Hodi, F.S.3
  • 45
    • 34547214205 scopus 로고    scopus 로고
    • Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans
    • Roncarolo M-G, Battaglia M. Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans. Nat Rev Immunol. 2007;7:585-598.
    • (2007) Nat Rev Immunol , vol.7 , pp. 585-598
    • Roncarolo, M.-G.1    Battaglia, M.2
  • 46
    • 84863987094 scopus 로고    scopus 로고
    • Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab is associated with a profound long-lasting depletion of Foxp3+ regulatory T cells: A mechanistic explanation for ipilimumab-induced severe enterocolitis?
    • Nancey S, Boschetti G, Cotte E, et al. Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab is associated with a profound long-lasting depletion of Foxp3+ regulatory T cells: a mechanistic explanation for ipilimumab-induced severe enterocolitis? Inflamm Bowel Dis. 2012;18:E1598-E1600.
    • (2012) Inflamm Bowel Dis , vol.18 , pp. E1598-E1600
    • Nancey, S.1    Boschetti, G.2    Cotte, E.3
  • 47
    • 84929157234 scopus 로고    scopus 로고
    • Anti-PD-1 therapy in melanoma
    • Homet Moreno B, Parisi G, et al. Anti-PD-1 therapy in melanoma. Semin Oncol. 2015;42:466-473.
    • (2015) Semin Oncol , vol.42 , pp. 466-473
    • Homet Moreno, B.1    Parisi, G.2
  • 48
    • 84957547203 scopus 로고    scopus 로고
    • Ipilimumab-induced gastrointestinal toxicities: A management algorithm
    • Klair JS, Girotra M, Hutchins LF, et al. Ipilimumab-induced gastrointestinal toxicities: a management algorithm. Dig Dis Sci. 2016;61:2132-2139.
    • (2016) Dig Dis Sci , vol.61 , pp. 2132-2139
    • Klair, J.S.1    Girotra, M.2    Hutchins, L.F.3
  • 49
    • 85006410852 scopus 로고    scopus 로고
    • Systematic review: Colitis associated with anti-CTLA-4 therapy
    • Gupta A, De Felice KM, Loftus EVJ, et al. Systematic review: colitis associated with anti-CTLA-4 therapy. Aliment Pharmacol Ther. 2015;42:406-417.
    • (2015) Aliment Pharmacol Ther , vol.42 , pp. 406-417
    • Gupta, A.1    De Felice, K.M.2    Loftus, E.V.J.3
  • 50
    • 84936936976 scopus 로고    scopus 로고
    • Ipilimumab-induced colitis in patients with metastatic melanoma
    • De Felice KM, Gupta A, Rakshit S, et al. Ipilimumab-induced colitis in patients with metastatic melanoma. Melanoma Res. 2015;25:321-327.
    • (2015) Melanoma Res , vol.25 , pp. 321-327
    • De Felice, K.M.1    Gupta, A.2    Rakshit, S.3
  • 51
    • 84963860995 scopus 로고    scopus 로고
    • Clinical, endoscopic, and histologic characteristics of ipilimumab-Associated colitis
    • Verschuren EC, van den Eertwegh AJ, Wonders J, et al. Clinical, endoscopic, and histologic characteristics of ipilimumab-Associated colitis. Clin Gastroenterol Hepatol. 2016;14:836-842.
    • (2016) Clin Gastroenterol Hepatol , vol.14 , pp. 836-842
    • Verschuren, E.C.1    Van Den Eertwegh, A.J.2    Wonders, J.3
  • 52
    • 84877038380 scopus 로고    scopus 로고
    • Ipilimumab-induced acute severe colitis treated by infliximab
    • Pages C, Gornet JM, Monsel G, et al. Ipilimumab-induced acute severe colitis treated by infliximab. Melanoma Res. 2013;23: 227-230.
    • (2013) Melanoma Res , vol.23 , pp. 227-230
    • Pages, C.1    Gornet, J.M.2    Monsel, G.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.